Outcomes based on albumin-bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC) Meeting Abstract
| Authors: | Chan, S. L.; Miksad, R.; Cicin, I.; Chen, Y.; Klumpen, H. J.; Kim, S.; Lin, Z. Z.; Youkstetter, J.; Sen, S.; Cheng, A. L.; El-Khoueiry, A. B.; Meyer, T.; Kelley, R. K.; Abou-Alfa, G. K. |
| Abstract Title: | Outcomes based on albumin-bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC) |
| Meeting Title: | 2019 ESMO Asia Congress |
| Journal Title: | Annals of Oncology |
| Volume: | 30 |
| Issue: | Suppl. 9 |
| Meeting Dates: | 2019 Nov 22-24 |
| Meeting Location: | Singapore |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2019-01-01 |
| Start Page: | mdz422.005 |
| Language: | English |
| ACCESSION: | WOS:000503487700124 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdz422.005 |
| Notes: | Meeting Abstract: 127TiP -- Appears on pages ix45-ix46 of the abstract book -- Source: Wos |
